INTRODUCTION: High numbers of tumor-associated macrophages (TAMs) have been associated with poor outcome in several solid tumors. In 2 previous studies, we showed that colony stimulating factor-1 (CSF1) is secreted by leiomyosarcoma (LMS) and that the increase in macrophages and CSF1 associated proteins are markers for poor prognosis in both gynecologic and nongynecologic LMS in a multicentered study. The purpose of this study is to evaluate the outcome of patients with LMS from a single institution according to the number of TAMs evaluated through 3 CSF1 associated proteins. METHODS: Patients with LMS treated at Stanford University with adequate archived tissue and clinical data were eligible for this retrospective study. Data from chart reviews included tumor site, size, grade, stage, treatment, and disease status at the time of last follow-up. The 3 CSF1 associated proteins (CD163, CD16, and cathepsin L) were evaluated by immunohistochemistry on tissue microarrays. Kaplan-Meier survival curves and univariate Cox proportional hazards models were fit to assess the association of clinical predictors as well as CSF1 associated proteins with overall survival. RESULTS: A total of 52 patients diagnosed from 1983 to 2007 were evaluated. Univariate Cox proportional hazards models were fit to assess the significance of grade, size, stage, and the 3 CSF1 associated proteins in predicting OS. Grade, size, and stage were not significantly associated with survival in the full patient cohort, but grade and stage were significant predictors of survival in the gynecologic (GYN) LMS samples (P = 0.038 and P = 0.0164, respectively). Increased cathepsin L was associated with a worse outcome in GYN LMS (P = 0.049). Similar findings were seen with CD16 (P < 0.0001). In addition, CSF1 response enriched (all 3 stains positive) GYN LMS had a poor overall survival when compared with CSF1 response poor tumors (P = 0.001). These results were not seen in non-GYN LMS. CONCLUSIONS: Our data form an independent confirmation of the prognostic significance of TAMs and the CSF1 associated proteins in LMS. More aggressive or targeted therapies could be considered in the subset of LMS patients that highly express these markers.
INTRODUCTION: High numbers of tumor-associated macrophages (TAMs) have been associated with poor outcome in several solid tumors. In 2 previous studies, we showed that colony stimulating factor-1 (CSF1) is secreted by leiomyosarcoma (LMS) and that the increase in macrophages and CSF1 associated proteins are markers for poor prognosis in both gynecologic and nongynecologic LMS in a multicentered study. The purpose of this study is to evaluate the outcome of patients with LMS from a single institution according to the number of TAMs evaluated through 3 CSF1 associated proteins. METHODS:Patients with LMS treated at Stanford University with adequate archived tissue and clinical data were eligible for this retrospective study. Data from chart reviews included tumor site, size, grade, stage, treatment, and disease status at the time of last follow-up. The 3 CSF1 associated proteins (CD163, CD16, and cathepsin L) were evaluated by immunohistochemistry on tissue microarrays. Kaplan-Meier survival curves and univariate Cox proportional hazards models were fit to assess the association of clinical predictors as well as CSF1 associated proteins with overall survival. RESULTS: A total of 52 patients diagnosed from 1983 to 2007 were evaluated. Univariate Cox proportional hazards models were fit to assess the significance of grade, size, stage, and the 3 CSF1 associated proteins in predicting OS. Grade, size, and stage were not significantly associated with survival in the full patient cohort, but grade and stage were significant predictors of survival in the gynecologic (GYN) LMS samples (P = 0.038 and P = 0.0164, respectively). Increased cathepsin L was associated with a worse outcome in GYN LMS (P = 0.049). Similar findings were seen with CD16 (P < 0.0001). In addition, CSF1 response enriched (all 3 stains positive) GYN LMS had a poor overall survival when compared with CSF1 response poor tumors (P = 0.001). These results were not seen in non-GYN LMS. CONCLUSIONS: Our data form an independent confirmation of the prognostic significance of TAMs and the CSF1 associated proteins in LMS. More aggressive or targeted therapies could be considered in the subset of LMS patients that highly express these markers.
Authors: Sumanta Goswami; Erik Sahai; Jeffrey B Wyckoff; Michael Cammer; Dianne Cox; Fiona J Pixley; E Richard Stanley; Jeffrey E Segall; John S Condeelis Journal: Cancer Res Date: 2005-06-15 Impact factor: 12.701
Authors: Inigo Espinosa; Andrew H Beck; Cheng-Han Lee; Shirley Zhu; Kelli D Montgomery; Robert J Marinelli; Kristen N Ganjoo; Torsten O Nielsen; C Blake Gilks; Robert B West; Matt van de Rijn Journal: Am J Pathol Date: 2009-05-14 Impact factor: 4.307
Authors: Andrew H Beck; Inigo Espinosa; Badreddin Edris; Rui Li; Kelli Montgomery; Shirley Zhu; Sushama Varma; Robert J Marinelli; Matt van de Rijn; Robert B West Journal: Clin Cancer Res Date: 2009-02-01 Impact factor: 12.531
Authors: Cheng-Han Lee; Inigo Espinosa; Suzan Vrijaldenhoven; Subbaya Subramanian; Kelli D Montgomery; Shirley Zhu; Robert J Marinelli; Johannes L Peterse; Neal Poulin; Torsten O Nielsen; Rob B West; C Blake Gilks; Matt van de Rijn Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531
Authors: Eytan Ben-Ami; Constance M Barysauskas; Sarah Solomon; Kadija Tahlil; Rita Malley; Melissa Hohos; Kathleen Polson; Margaret Loucks; Mariano Severgnini; Tara Patel; Amy Cunningham; Scott J Rodig; F Stephen Hodi; Jeffrey A Morgan; Priscilla Merriam; Andrew J Wagner; Geoffrey I Shapiro; Suzanne George Journal: Cancer Date: 2017-04-25 Impact factor: 6.860
Authors: Andrej Ozaniak; Jitka Smetanova; Robin Bartolini; Michal Rataj; Linda Capkova; Jaromir Hacek; Martina Fialova; Lenka Krupickova; Ilja Striz; Robert Lischke; Jirina Bartunkova; Zuzana Strizova Journal: J Cancer Res Clin Oncol Date: 2022-08-20 Impact factor: 4.322
Authors: Michael J Wagner; Yuzheng Zhang; Lee D Cranmer; Elizabeth T Loggers; Graeme Black; Sabrina McDonnell; Shannon Maxwell; Rylee Johnson; Roxanne Moore; Pedro Hermida de Viveiros; Lauri Aicher; Kimberly S Smythe; Qianchuan He; Robin L Jones; Seth M Pollack Journal: Clin Cancer Res Date: 2022-06-01 Impact factor: 13.801
Authors: Seth M Pollack; Qianchuan He; Jennifer H Yearley; Ryan Emerson; Marissa Vignali; Yuzheng Zhang; Mary W Redman; Kelsey K Baker; Sara Cooper; Bailey Donahue; Elizabeth T Loggers; Lee D Cranmer; Matthew B Spraker; Y David Seo; Venu G Pillarisetty; Robert W Ricciotti; Benjamin L Hoch; Terrill K McClanahan; Erin Murphy; Wendy M Blumenschein; Steven M Townson; Sharon Benzeno; Stanley R Riddell; Robin L Jones Journal: Cancer Date: 2017-05-02 Impact factor: 6.860
Authors: Amanda R Dancsok; Dongxia Gao; Anna F Lee; Sonja Eriksson Steigen; Jean-Yves Blay; David M Thomas; Robert G Maki; Torsten O Nielsen; Elizabeth G Demicco Journal: Oncoimmunology Date: 2020-04-12 Impact factor: 8.110